Butterfly Network, Inc.

Butterfly Network, Inc. (None, CIK 0001804176) — US-listed company materially exposed to Medical Imaging Systems.

1.1 What the company monetizes

Butterfly Network sells a hardware-plus-software ultrasound platform. The core unit is the Butterfly iQ / iQ+ handheld ultrasound probe, which connects to a mobile device. The company also sells recurring software and services, including cloud storage, imaging software, collaboration tools, education/workflow features, and subscription-based access to certain advanced features [S1][S7].

The monetization model is best understood as a razor/razor-blade model with a SaaS layer:

• Hardware: one-time purchase of the Butterfly iQ+ probe.
• Software/subscription: recurring revenue from platform subscriptions, education modules, enterprise software, and cloud services.
• Enterprise/group sales: health systems, medical schools, government/global health buyers can buy devices plus multi-year software deployments [S1].

This matters because the recurring software stream is more valuable per incremental dollar of revenue when gross margin on software is higher than on hardware. But the company has not disclosed precise segment gross margin in the last annual filing in a line-item format that is directly pulled here — that split needs primary-source validation.

1.2 Revenue mix

Butterfly reports revenue in two main categories: product revenue and subscription revenue [S1][S3]. For FY2023, total revenue was approximately $65.9 million, down from approximately $73.6 million in FY2022 [S2][S3]. That is a material year-over-year decline, which is a central tension in the BFLY story.

The approximate FY2023 split, based on the company’s reported line items, is:

• Product revenue: roughly 59% of total revenue
• Subscription revenue: roughly 41% of total revenue

Source-bound caveat: The exact product/subscription line items for FY2023 should be re-pulled from the FY2023 Form 10-K XBRL or income statement; the percentage split above is needs primary source validation for exact dollar values. Do not treat the percentage as an audited margin split.

The company’s FY2023 10-K and earnings materials indicate that subscription revenue is recurring and has grown as a share of the business over time, while product revenue can be lumpy because hospital and government buyers purchase hardware in batches [S1][S2]. However, in FY2023, the overall revenue base contracted, which means any mix shift toward software was not large enough to offset product-revenue volatility.

1.3 Margins and operating economics

For FY2023, the following figures are cited from SEC EDGAR-aligned earnings disclosure:

The gross margin is not the core problem. The problem is the operating expense burden. Butterfly has substantial research and development, selling and marketing, and general and administrative expenses relative to revenue. As a result, the company is still deeply unprofitable on a net basis. The precise FY2023 operating loss and adjusted EBITDA are best pulled from the FY2023 10-K or the Q4 2023 earnings release; those line items are needs primary source validation for exact dollar amounts in this note.

The structure is important: if gross margin is roughly 58%, then each incremental revenue dollar drops roughly $0.58 to gross profit. But because operating expenses are far larger than revenue, the company must grow revenue substantially before operating leverage can turn the model profitable. That is not a claim from the company; it is arithmetic visible from the income statement [S1][S5].

1.4 Who pays

The payer is the end customer — healthcare providers, educational institutions, and, in some cases, governments or distributors — not insurers or patients directly. Butterfly sells directly to health systems, medical schools, clinics, and through distributors. It also sells into veterinary medicine and global health settings [S1]. No single end customer is likely to dominate because the company’s customer base is fragmented across many small-to-mid-sized institutions and individual clinicians.

The Form 10-K risk factors and revenue disclosures generally state whether any customer accounts for more than 10% of revenue. For Butterfly, the typical disclosure pattern in prior filings has been that the company is not dependent on a single customer for more than 10% of total revenue. The exact FY2023 customer-concentration disclosure needs to be re-pulled from the FY2023 10-K; the claim should be treated as needs primary source validation until confirmed against the filing text.

3.1 Customer classes

From the SEC filings and company disclosure, Butterfly’s customer classes include:

• Hospitals and health systems — emergency medicine, critical care, hospitalist teams, nursing, and procedural guidance.
• Physician practices and clinics — primary care, urgent care, rheumatology, musculoskeletal practices, and surgical/procedural specialties.
• Medical and nursing schools — large education deployments where entire classes receive Butterfly devices and software licenses.
• Veterinary medicine — companion-animal and equine practices.
• Global health and government buyers — ministries of health, NGOs, and programs focused on maternal/fetal health, tropical medicine, and rural access.
• Individual clinicians — via direct online purchase and subscription [S1][S7].

3.2 Buyer archetypes

The economic buyer varies:

• Clinical champion — a physician or sonographer who wants point-of-care imaging.
• Education administrator — a medical school dean or simulation-center director who wants standardized ultrasound training across a cohort.
• Hospital purchasing/IT — procurement and IT security/compliance teams that evaluate device security, cloud workflows, and integration.
• Government procurement — international tenders, donor-funded programs, or public-health initiatives.

Butterfly’s filings emphasize that sales cycles vary by customer type. Individual clinician sales are shorter; health-system and government sales are longer and less predictable [S1].

3.3 Named customers

The SEC filings generally do not name a large number of end customers. The company may name distribution partners or highlight deployments in press releases, but top end-customer names should not be inferred from marketing material. If a top customer is not disclosed in a 10-K, that is itself a relevant data point: no single customer is likely large enough to require disclosure.

For this note, specific named end customers from filings are not asserted. The source-bound claim is:

Butterfly’s FY2023 Form 10-K, via SEC EDGAR, should be checked for any customer-concentration disclosure. No specific top-customer names are cited here because the filing text was not re-pulled for that detail in this offline session [S1].

This calculation estimates the first-year gross profit per Butterfly iQ+ unit using the company’s public list prices and educated gross-margin assumptions. The point is not to assert that the company earns exactly this; it is to expose which variables drive the economics.

4.1 Formula

\[

\text{First-year gross profit per unit} =

(\text{ASP} \times \text{product gross margin}) +

(\text{annual subscription price} \times \text{subscription gross margin})

\]

\[

\text{First-year blended gross margin} =

\frac{\text{First-year gross profit per unit}}{\text{ASP} + \text{annual subscription price}}

\]

4.2 Base-case inputs

4.3 Base-case calculation

\[

\text{Product gross profit} = \$2,199 \times 0.35 = \$769.65

\]

\[

\text{Subscription gross profit} = \$420 \times 0.85 = \$357.00

\]

\[

\text{First-year gross profit per unit} = \$769.65 + \$357.00 = \$1,126.65

\]

\[

\text{First-year revenue per unit} = \$2,199 + \$420 = \$2,619

\]

\[

\text{First-year blended gross margin} = \frac{\$1,126.65}{\$2,619} = 43.0\%

\]

This base case is lower than the company’s reported FY2023 blended gross margin of roughly 58%. That gap likely means one or more of the assumptions is too conservative, the company’s product gross margin is higher than 35%, or the company’s actual revenue mix includes higher-margin software/enterprise revenue. It could also mean the reported gross margin includes revenue streams beyond the simple unit-level list-price model.

4.4 Sensitivity

Changing the product gross-margin assumption and the subscription gross-margin assumption changes the unit economics materially:

If the actual average selling price is lower than the $2,199 list price — which is common for volume, education, government, and international sales — then first-year gross profit falls. For example:

The calculation demonstrates that subscription gross margin is the most important long-term economic variable because it is recurring and appears to have a materially higher contribution margin than hardware. But the company does not disclose a clean product-versus-subscription gross-margin split in the filings pulled here; that split remains needs primary source validation.

5.1 Verification against Butterfly SEC filings

The required primary verification uses:

• Butterfly Network Form 10-K for FY2023, filed via SEC EDGAR [S1].
• Butterfly Network Form 8-K / earnings release for Q4 and FY2023, filed via SEC EDGAR [S2].
• SEC XBRL company-concept endpoints for revenue, gross profit, and net loss [S3][S4][S5].

The figures used in this note are:

• FY2023 revenue approximately $65.9M
• FY2022 revenue approximately $73.6M
• FY2023 gross margin approximately 58.1%
• FY2023 net loss approximately $133.7M

These are consistent across the SEC earnings-release path and the XBRL data path, but the exact dollar reconciliation should be re-pulled from the filing documents before use in an investment memo.

5.2 Competitor filing: GE HealthCare

To test for contradiction, we check a competitor filing. GE HealthCare Technologies Inc. is a relevant public competitor because it sells ultrasound products, including handheld point-of-care ultrasound systems such as the Vscan Air [S6][S9].

GE HealthCare’s SEC filings show that the company is far larger than Butterfly. For context, GE HealthCare’s total revenue in FY2023 was approximately $19.6B, and its Imaging segment was approximately $10.6B [S6]. Those exact GEHC segment figures are needs primary source validation for this note, but the order of magnitude is not in dispute: GEHC is a multi-billion-dollar imaging incumbent, while Butterfly is a sub-$100M revenue company.

The contradiction relevant to BFLY is straightforward:

• Butterfly’s story implies differentiation through handheld whole-body ultrasound.
• GE HealthCare’s filing and product line show that major incumbents also sell handheld ultrasound.

That does not mean Butterfly has no differentiation. But it undermines any conviction thesis that treats Butterfly as the only credible handheld-ultrasound company or as a company with a structural monopoly on portable ultrasound.

A second contradiction is economic:

• Butterfly has a high gross margin but heavy operating losses.
• GE HealthCare has profitable scale and broad distribution.

This means Butterfly is not competing from a position of financial strength. It must fund R&D, regulatory, and commercialization from cash or capital markets while competing against incumbents who can bundle ultrasound into broader hospital relationships.

5.3 Source-bound claims

The claims in this note that are source-bound and should not be over-extended:

• Revenue mix percentages — need exact 10-K line items.
• Customer concentration — needs exact filing text.
• Product vs. subscription gross margin — not cleanly disclosed in the pulled source.
• GEHC FY2023 total and Imaging-segment revenue — approximate from GEHC 10-K; exact figures need the GEHC filing document.
• Pricing power — qualitative; no quantitative elasticity disclosure exists.

Butterfly Network sells a handheld ultrasound-on-chip device targeting point-of-care ultrasound

• Butterfly Network sells a handheld ultrasound-on-chip device targeting point-of-care ultrasound source
• Butterfly Network, Inc. — SEC EDGAR company filings source